EDUCATE: The MEDTRONIC Endeavor Drug Eluting Stenting: Understanding Care, Antiplatelet Agents and Thrombotic Events

ENROLLMENT INCLUSION CRITERIA * Patient is older than 18 years. * The patient or patient's legal representative has consented to participate and has authorized the collection and release of his medical information by signing the "Subject Informed Consent Form". * Patients undergoing percutaneous intervention with Endeavor stent deployment (or has within 24 hours). * The patient is willing and able to cooperate with study procedures and required follow up visits. ENROLLMENT EXCLUSION CRITERIA * Index procedure stent placement with stent diameter \< 2.5 mm or \> 3.5 mm. * Pregnant women. * Current medical condition with a life expectancy of less than 3 years. * The patient is currently participating in another investigational device or drug study that clinically interferes with the EDUCATE Study. The patient may only be enrolled in the EDUCATE Study once. * Patients with hypersensitivity or allergies to one of the drugs or components indicated in the Instructions for Use. * Patients in whom anti-platelet and/or anticoagulation therapy is contraindicated. * Patients treated with any stent other than the Endeavor stent during the index procedure. RANDOMIZATION INCLUSION CRITERIA AT 12 MONTHS * Subject is "12 Month Clear". * Subjects without known contraindication to dual antiplatelet therapy for at least 18 months after randomization. RANDOMIZATION EXCLUSION CRITERIA AT 12 MONTHS * Pregnant women. * Subject switched thienopyridine type or dose within 6 months prior to randomization. * Planned surgery necessitating discontinuation of antiplatelet therapy within the 18 months following randomization. * Percutaneous coronary intervention or cardiac surgery between 6 weeks post index procedure and randomization. * Planned surgery necessitating discontinuation of antiplatelet therapy within the 21 months following randomization. * Current medical condition with a life expectancy of less than 3 years. * Subjects on warfarin or similar anticoagulant therapy.